This activity was originally presented at the 2022 ASHP Midyear Clinical Meeting & Exposition.
Program Description
Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancers and is the leading cause of cancer death in the United States, with over 131,000 deaths in 2021. A recent expansion in treatment options has occurred following the shift from traditional systemic platinum doublet chemotherapy towards immune checkpoint inhibitors (ICIs). This has led to an increase in the 5-year survival rate and continues to shape the delivery of care. Pharmacists who provide direct care to patients with NSCLC must be informed about the role of biomarkers in therapy selection and the role of ICIs in frontline therapy. Patients treated with ICI therapy are at risk of experiencing unique toxicities, such as checkpoint inhibitor pneumonitis (CIP); certain special considerations must be evaluated prior to ICI use. With thorough clinical insight, pharmacists can assist in the appropriate therapy selection and identification and management of unique toxicities. This activity, which features patient case discussions, will prepare pharmacists to guide the treatment of NSCLC through the connection of PD-L1 expression with ICI treatment selection, application of guideline recommendations, and management of CIP.
Target audience: Health System Pharmacist, Oncology Pharmacist
Type of activity: Application
Release date: December 22, 2022
Expiration date: March 31, 2024
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Correlate PD-L1 expression with frontline immune checkpoint inhibitor treatment selection in metastatic non-small cell lung cancer (NSCLC)
- Apply guideline recommendations and patient-specific factors to treatment selection for a patient with metastatic NSCLC who has not received prior systemic therapy
- Explore strategies to aid in the early identification and treatment of checkpoint inhibitor pneumonitis among patients with NSCLC
Jordan McPherson, PharmD, BCOP
Oncology Clinical Pharmacist, Huntsman Cancer Institute
Adjunct Assistant Professor, College of Pharmacy, University of Utah
Salt Lake City, Utah
Jocelyn Mohs, PharmD, BCOP
Director of Pharmacy, PGY-2 Oncology Residency Program Director
Sanford Medical Center and Roger Maris Cancer Center
Fargo, North Dakota
Allison Schepers, PharmD, BCOP
Clinical Pharmacist Specialist, Medical Oncology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-617-H01-P. The activity is available for CE credit through March 31, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Jordan McPherson, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Hitachi, Ltd. (Research Support)- Content unrelated to presentation
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Jocelyn Mohs, PharmD, BCOP
Allison Schepers, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA, CHCP; Evelina Kolychev, PharmD, BCOP; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms